Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2015
ASCO 2015 Highlights
Family Patient-Related Factors Main Barriers to End-of-Life Discussions
By
Meg Barbor, MPH
End-of-Life Care
,
Palliative Care
,
Policies & Guidelines
December 2015, Vol 6, No 11
Boston, MA—Family- and patient-related factors were identified as the most significant barriers to early end-of-life discussions, as well as to the timely discontinuation of cancer-directed therapies in the palliative setting, according to the results of a multicenter survey of oncologists in Ontario, Canada.
Read Article
American Cancer Society Updates Breast Cancer Screening Guidelines for Women at Average Risk
By
Laura Morgan
Breast Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
Breast cancer is the leading cause of premature death in women. According to the American Cancer Society (ACS), more than 40,000 US women will die of breast cancer in 2015.
Read Article
Afatinib vs Erlotinib as Second-line Therapy of Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung: Analysis from the LUX-Lung 8 Trial
Conference Correspondent
Read Article
CD19-Targeted 19-28z CAR-Modified T-Cells in Adult Patients with Relapsed/Refractory B-Cell ALL: Impact of MRD-Negative CR and Allogeneic Stem-Cell Transplant on Outcomes
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Frontline Inotuzumab Ozogamicin plus Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with ALL
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Dose-Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated ALL: A DFCI ALL Consortium Phase 2 Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Total Therapy GIMEMA LAL 1509 Protocol for De Novo Adult Ph+ ALL Patients: Updated Results and Genetic-Based Prognostic Stratification
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Frontline Hyper-CVAD plus Ofatumumab for Adult Patients with CD-20–Positive ALL
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Final Results of the OPTIM Imatinib Study in Patients with CML: Personalized Daily Doses of Imatinib by Therapeutic Drug Monitoring
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory ALL Treated with Blinatumomab
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Page 176 of 330
173
174
175
176
177
178
179
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Gaps in Biomarker Testing and Targeted Therapy for Gastric Cancer
Ashley Gamble, PhD
,
John Perez, MBA, MSDS
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma